Ligand-guided optimization of CXCR4 homology models for virtual screening using a multiple chemotype approach

Marco A C Neves1, Sérgio Simões, M Luisa Sá e Melo

  • 1Centro de Estudos Farmacêuticos, Laboratório de Química Farmacêutica, Faculdade de Farmácia, Universidade de Coimbra, Pólo das Ciências da Saúde, Coimbra, Portugal. mneves@ff.uc.pt

Insights

This study developed optimized molecular models for the CXCR4 receptor, aiding in the discovery of new antagonists for conditions like HIV and cancer. These models enhance structure-based drug design and virtual screening efforts.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • CXCR4, a G-protein coupled receptor, is crucial in HIV infection, cancer metastasis, and immune cell trafficking.
  • The lack of an X-ray crystal structure for CXCR4 necessitates theoretical modeling for structure-function analysis.
  • Understanding CXCR4 is vital for developing novel therapeutic antagonists.

Purpose of the Study:

  • To develop optimized ligand-receptor models for CXCR4 using integrated experimental and computational approaches.
  • To elucidate the molecular determinants governing small molecule binding and antagonism of CXCR4.
  • To enhance the identification of effective CXCR4 antagonists through improved virtual screening.

Main Methods:

  • Employed a ligand-guided homology modeling approach to refine the CXCR4 binding pocket.
  • Integrated experimental data with molecular modeling techniques.
  • Utilized multiple test sets of small compounds from single chemotypes for model refinement.

Main Results:

  • Developed optimized CXCR4 ligand-receptor models capable of discriminating between known antagonists and decoys.
  • The ligand-guided modeling approach effectively reshaped the CXCR4 binding pocket.
  • Refined models demonstrated superior early enrichment performance in virtual screening.

Conclusions:

  • The developed models serve as a valuable tool for structure-based drug design targeting CXCR4.
  • This approach facilitates efficient virtual ligand screening for novel CXCR4 antagonists.
  • The findings support the development of new therapeutics for CXCR4-related diseases.